Jing Liu

ORCID: 0009-0007-1423-4923
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • PI3K/AKT/mTOR signaling in cancer
  • Lymphoma Diagnosis and Treatment

AbbVie (United States)
2023

Abstract Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR) signaling pathway, we...

10.1158/1535-7163.mct-22-0642 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2023-09-21

<div>Abstract<p>Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR)...

10.1158/1535-7163.c.7005673.v1 preprint EN 2024-01-03

<div>Abstract<p>Small molecule inhibitors of Bruton's tyrosine kinase (BTK) have been approved for the treatment multiple B-cell malignancies and are being evaluated autoimmune inflammatory diseases. Various BTK (BTKi) distinct potencies, selectivity profiles, binding modes within ATP-binding site. On basis latter feature, BTKis can be classified into those that occupy back-pocket, H3 pocket, hinge region only. Hypothesizing differing may differential impact on receptor (BCR)...

10.1158/1535-7163.c.7005673 preprint EN 2024-01-03
Coming Soon ...